EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors

Ryan K Shields iD, Ellen G Kline, Kevin M Squires, Daria Van Tyne iD, Yohei Doi iD

JAC-Antimicrobial Resistance · 04.09.2023 · 5 (5)

DOI: 10.1093/jacamr/dlad107 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAC-Antimicrobial Resistance, online erschienen am 03.10.2023. Verfasst von Ryan K Shields und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, National Institutes of Health, Cystic Fibrosis Foundation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cefiderocol demonstrates excellent activity against MDR Pseudomonas aeruginosa; however, the activity against isolates from patients previously treated with β-lactam agents is unknown. We aimed to determine the activity of cefiderocol against P. aeruginosa collected before and after treatment with traditional β-lactams and new β-lactam/β-lactamase inhibitors.

Methods

Cefiderocol MICs were determined in triplicate in iron-depleted cation-adjusted Mueller–Hinton broth and compared with β-lactam MICs tested by standard methods. All isolates underwent WGS analysis to identify mutations associated with resistance.

Results

One hundred and seventy-eight P. aeruginosa isolates were evaluated; 48% (86/178) were non-susceptible to ceftazidime/avibactam, ceftolozane/tazobactam and/or imipenem/relebactam. The cefiderocol MIC50 and MIC90 were 0.12 and 1 mg/L, respectively. Median cefiderocol MICs did not vary against isolates classified as MDR, XDR, or those non-susceptible to ceftazidime/avibactam, ceftolozane/tazobactam and/or imipenem/relebactam when compared with non-MDR isolates. Against isolates collected from patients previously treated with ceftolozane/tazobactam, cefiderocol MICs were increased 4-fold compared with baseline. Cross-resistance to cefiderocol was identified in 21% (3/14) of patients who developed treatment-emergent resistance to ceftolozane/tazobactam. Overall, 6% (11/178) of isolates demonstrated cefiderocol MICs ≥2 mg/L, which were disproportionately collected from patients previously treated with ceftolozane/tazobactam (73%; 8/11). Isolates with reduced cefiderocol susceptibility harboured mutations in ampC, tonB-dependent receptors, the response regulator pirR and ftsI.

Conclusions

Cefiderocol demonstrates excellent in vitro activity against P. aeruginosa isolates exposed to other novel β-lactam agents; however, some exceptions were identified. Cross-resistance between cefiderocol and ceftolozane/tazobactam was evident, but not with ceftazidime/avibactam or imipenem/relebactam. Reduced cefiderocol susceptibility was mediated by mutations in ampC and tonB-dependent receptors.

Autor:innen und Institutionen

  • Department of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Center for Innovative Antimicrobial Therapy, University of Pittsburgh, Pittsburgh, PA, USA.
  • Antibiotic Management Program, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
  • Center for Evolutionary Biology and Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
  • Departments of Microbiology and Infectious Diseases, Fujita Health University School of Medicine, Toyoake, Aichi, Japan.

ORCID-Profile: Ryan K Shields, Daria Van Tyne, Yohei Doi

Förderung

  • NIAID NIH HHS
  • National Institutes of Health
  • Cystic Fibrosis Foundation

Zitieren

APA

Shields, R. K., Kline, E. G., Squires, K. M., Van Tyne, D., & Doi, Y. (2023). In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors. JAC-Antimicrobial Resistance, 5(5). https://doi.org/10.1093/jacamr/dlad107

Vancouver

Shields RK, Kline EG, Squires KM, Van Tyne D, Doi Y. In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors. JAC-Antimicrobial Resistance. 2023;5(5). doi:10.1093/jacamr/dlad107

BibTeX
@article{Shields2023,
  author = {Shields, Ryan K and Kline, Ellen G and Squires, Kevin M and Van Tyne, Daria and Doi, Yohei},
  title = {In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors},
  journal = {JAC-Antimicrobial Resistance},
  year = {2023},
  volume = {5},
  number = {5},
  doi = {10.1093/jacamr/dlad107}
}
Kostenlos starten →